MX170073B - Modificador de respuesta biologica y metodo para producirlo - Google Patents

Modificador de respuesta biologica y metodo para producirlo

Info

Publication number
MX170073B
MX170073B MX006821A MX682187A MX170073B MX 170073 B MX170073 B MX 170073B MX 006821 A MX006821 A MX 006821A MX 682187 A MX682187 A MX 682187A MX 170073 B MX170073 B MX 170073B
Authority
MX
Mexico
Prior art keywords
biological response
response modifier
patient
vesicles
cell
Prior art date
Application number
MX006821A
Other languages
English (en)
Inventor
Richard W Urban
Original Assignee
Cell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Technology Inc filed Critical Cell Technology Inc
Publication of MX170073B publication Critical patent/MX170073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un modificador de respuesta biológica para tratar un paciente, que comprende vesículas de membranas naturales y ribosomas en un amortiguador de suspensión, dichas vesículas de membrana y ribosomas son endógenos a un microorganismo seleccionado el cual no evoca una respuesta desviadora inmunológica significante en el paciente y substancialmente no es patógena a los seres humanos, este microorganismo seleccionado también es uno cuyas vesículas de membrana son capaces de formarse a partir del material de la membrana celular, las vesículas son endocitosadas fácilmente por la línea de celulas monocíticas y macrófagas del paciente, este modificador de respuesta biológica está substancialmente exento de endotoxina, celulas intactas, paredes celulares y fragmentos de membranas celulares y dicho modificador de respuesta biológica además exhibe un diámetro medio mayor de 170 nm, en el análisis del tamaño de partículas.
MX006821A 1986-06-09 1987-06-08 Modificador de respuesta biologica y metodo para producirlo MX170073B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87213186A 1986-06-09 1986-06-09
US07/057,344 US4971801A (en) 1986-06-09 1987-06-02 Biologic response modifier

Publications (1)

Publication Number Publication Date
MX170073B true MX170073B (es) 1993-08-06

Family

ID=26736367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX006821A MX170073B (es) 1986-06-09 1987-06-08 Modificador de respuesta biologica y metodo para producirlo

Country Status (11)

Country Link
US (1) US4971801A (es)
EP (1) EP0249447A3 (es)
KR (1) KR880701110A (es)
AU (2) AU606075B2 (es)
DK (1) DK66788D0 (es)
FI (1) FI880412A0 (es)
IE (1) IE871529L (es)
IN (1) IN165076B (es)
MX (1) MX170073B (es)
NO (1) NO880517L (es)
NZ (1) NZ220614A (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7239191A (en) * 1990-01-25 1991-08-21 University Of Colorado Foundation, Inc., The Method for preventing immune suppression in trauma patients
AU7675891A (en) * 1990-03-28 1991-10-21 Atif M Hussein Methods for protecting against chemotherapy-induced hair loss
AU8948491A (en) * 1990-11-09 1992-06-11 Cell Technology, Inc. Method for preventing drug-induced or radiation myelosuppression
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US6183756B1 (en) * 1997-05-01 2001-02-06 Dynagen, Inc. Methods for prevention and/or treatment of thrombocytopenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4323561A (en) * 1977-09-06 1982-04-06 Temple University Of The Commonwealth System Of Higher Education Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
FR2471785A1 (fr) * 1979-12-21 1981-06-26 Fabre Sa Pierre Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
JPS5849311A (ja) * 1981-09-18 1983-03-23 Eisai Co Ltd 安全なるリポソ−ムの製造法

Also Published As

Publication number Publication date
FI880412A (fi) 1988-01-29
DK66788A (da) 1988-02-09
NO880517L (no) 1988-03-21
EP0249447A2 (en) 1987-12-16
AU606075B2 (en) 1991-01-31
AU7524691A (en) 1991-09-19
EP0249447A3 (en) 1989-10-18
US4971801A (en) 1990-11-20
IE871529L (en) 1987-12-09
DK66788D0 (da) 1988-02-09
KR880701110A (ko) 1988-07-25
NZ220614A (en) 1989-08-29
IN165076B (es) 1989-08-12
AU7786487A (en) 1988-01-11
FI880412A0 (fi) 1988-01-29
NO880517D0 (no) 1988-02-05

Similar Documents

Publication Publication Date Title
Shoenberg An electron microscope study of the influence of divalent ions on myosin filament formation in chicken gizzard extracts and homogenates
ES2084838T3 (es) Metilpirrolidinonquitosano, proceso para su produccion y usos del mismo.
ATE319476T1 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
Jenkins Fine structure of division in ciliate protozoa: I. Micronuclear mitosis in blepharisma
MX170073B (es) Modificador de respuesta biologica y metodo para producirlo
Conti et al. Biology of budding bacteria III. Fine structure of Rhodomicrobium and Hyphomicrobium spp
ES2179215T3 (es) Gel de acido hialuronico con enlaces cruzados fotorreticulado y procedimiento para su preparacion.
Labat-Robert et al. Fibronectin-like protein in Porifera: its role in cell aggregation.
AR025837A1 (es) Un material tramado al azar esponjado
GB8413319D0 (en) Biological material
ES2146756T3 (es) Xilanasas termoestables.
DE69120146D1 (de) Erzeugung xenogener antikörper
ES2061598T3 (es) Produccion de anticuerpos quimericos por recombinacion homologa.
Outka et al. The Ameba-to-Flagellate Transformation in Tetramitus rostratus: II. Microtubular Morphogenesis
DE3873672D1 (de) Stilbensynthase-gen.
ES2189890T3 (es) Un material biologico comprendiendo un cultivo eficaz de celulas madre de medula osea parcialmente o complemtamente diferenciadas en celulas de tejido conectivo y una matriz tridimensional biocompatible y biodegradable consistente en un derivado del acido hialuronico.
ES2073568T3 (es) Carbono de sustitucion en silicio.
BR8806136A (pt) Metodo para regeneracao de uma planta algodoeira a partir de celulas somaticas
PT81367B (pt) Processo para produzir vacinas orais usando adenovirus como vector
PE87198A1 (es) Aciltransferasa y gen que codifica aciltransferasa
Nakamura et al. Ultrastructure of Chlamydomonas eugametos palmelloids induced by chloroplatinic acid treatment
EP0374178A4 (en) Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
ATE268811T1 (de) Therapeutische anwendungen von chimänischer organogenese
EP0141182A3 (en) Process and medium for culturing ant venom gland cells
Shepard et al. Electron microscopically revealed structural elements of Bacterium tularense and their in vitro and in vivo role in immunologic reactions